This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Entegris Acquires ATMI For $1B

NEW YORK (The Deal) -- Entegris  (ENTG - Get Report) announced Tuesday it would pay $1.15 billion for ATMI (ATMI - Get Report) sending shares of the two semiconductor suppliers sharply higher.

Entegris rose $1.13, or 11%, to $11.41, while ATMI gained $6.86, or 25.5%, to $33.79.

ATMI investors will receive $34 per share, a premium of more than 26% above Monday's close. The valuation equates to $850 million when backing out ATMI's cash, which includes $170 million in expected proceeds from the pending sale of the target's life sciences business to Pall (PLL - Get Report).

Entegris CEO Bertrand Loy said the purchase will help the buyer manage the growing cost and complexity of new semiconductor manufacturing processes.

ATMI provides specialty materials for semiconductor and microelectronics manufacturers. The Danbury, Conn., company generated $86 million in 2013 Ebitda, against sales of $361 million. Entegris said it projects that it will have more than $1 billion in sales following the purchase.

Stifel, Nicolaus analyst Patrick Ho observed in a Tuesday report that the deal's valuation of 2.7 times sales falls within the range of 2-to-3 times sales that is typical for the semiconductor capital sector.

ATMI disclosed that it had retained Barclays Capital to explore strategic options in November.

Pall agreed to pay $185 million for ATMI's life sciences unit in December. The sale to Entegris is conditioned upon closing the deal with Pall.

Billerica, Mass.-based Entegris said it expects to complete the purchase of ATMI in the second quarter of 2014.

Barry O'Brien and Thomas Stokes of Goldman Sachs  (GS) and a team from Ropes & Gray led by Craig Marcus, Tom Draper, Eric Elfman, Renata Ferrari and Peter Alpert advised Entegris.

Goldman is also arranging financing for Entegris.

ATMI retained Barclays bankers Ken Grahame, Paul Collins and Laurence Braham, and Weil Gotshal & Manges lawyers including Thomas Roberts, Matthew Gilroy, Mark Hoenig, Paul Wessel, John Brockland, Annemargaret Connolly and Richard Ginsburg.

Barclays and Weil also advised ATMI on the life sciences divestiture.

-- Lou Whiteman contributed to this report.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
ATMI $33.98 0.00%
ENTG $13.29 0.00%
PLL $97.62 -0.80%
AAPL $125.80 -2.25%
FB $77.56 -1.59%

Markets

DOW 17,928.20 -142.20 -0.79%
S&P 500 2,089.46 -25.03 -1.18%
NASDAQ 4,939.3270 -77.6020 -1.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs